📰 Slate Development News
Page 2 - Slate Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Slate Development. Real-time updates on events, politics, business and more.
September 14, 2022
Mumbai (Maharashtra) [India], September 14 (ANI/Newsvoir): Pharma Intelligence, now Citeline, one of the leading business intelligence providers and knowledge partners, is pleased to announce the 11th Pharma IPR India 2022, and the 4th edition of Biopharma Conclave 2022 organised by the Informa Markets division of Informa PLC. Biopharma Conclave 2022 will take place on September 15 and 16 at Aster, the St. Regis Mumbai, and Pharma IPR India 2022 is set convene from September 14th to 16th, 2022 a...
September 7, 2022
OMAHA — A midtown real estate team best known for turning a forsaken urban corridor into the trendy Blackstone commercial district is venturing into different territory. GreenSlate Development wants to
August 25, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved...
August 25, 2022
HORSHAM, PA - The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration has approved IMBRUVICA for the treatment of pediatric patients one... | August 25, 2022
August 4, 2022
Approval marks the first all-oral, once-daily, fixed-duration Bruton's tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL The Janssen Pharmaceutical Companies of Johnson
August 4, 2022
Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLLBEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation...
June 24, 2022
The positive opinion is based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the efficacy and safety of ibrutinib plus venetoclax in patients with previously untreated CLL1
June 3, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study (Abstract #7502), which...
June 3, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study (Abstract #7502), which...